全球创新药研发进展密集落地，关注恒生创新药ETF（159316）、创新药ETF易方达（516080）投资价值

Group 1 - The core viewpoint of the news is that the innovative drug sector is experiencing a short-term adjustment, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index down by 1% and the CSI Innovative Drug Industry Index down by 0.8% as of 14:40 [1] - Despite the recent decline, there is a strong willingness among investors to allocate funds to the innovative drug sector, with net inflows exceeding 6 billion yuan in Hong Kong and over 3 billion yuan in A-shares since November [1] - Significant advancements in global innovative drug research have been reported, including successful Phase III studies for Roche's new oral SERD drug and FDA approval for Arrowhead's first long-acting lipid-lowering siRNA therapy [1] Group 2 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is one of the first "pure" innovative drug indices with 100% purity, focusing on leading innovative drug companies in Hong Kong [2] - The CSI Innovative Drug Industry Index targets the A-share innovative drug sector, consisting of no more than 50 leading companies primarily engaged in innovative drug research and development [2] - The Hang Seng Innovative Drug ETF (159316) and the E Fund Innovative Drug ETF (516080) track these indices, providing investors with convenient tools to invest in cutting-edge innovative drug companies [2]